
Abdou O. Abdelhamid,^{a*} Sobhi M. Gomha,^a and Saher M. Kandeel^b

^aDepartment of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt ^bChemistry of Natural Compounds, Department National Research Center, Dokki, Cairo, Egypt *E-mail: Abdelhamid45@gmail.com

Received July 9, 2015

DOI 10.1002/jhet.2740

Published online 00 Month 2016 in Wiley Online Library (wileyonlinelibrary.com).



2-(2-(1-(1H-Indol-3-yl)ethylidene)-hydrazinyl)-4-substituted 5-(aryldiazenyl)thiazoles and 5-((1-(1H-Indol-3-yl)ethylidene)hydrazono)-2-substituted-4-phenyl-4,5-dihydro-1,3,4-thiadiazoles were synthesized via reaction of hydrazonoyl halides and 2-(1-(1H-Indol-3-yl)ethylidene)hydrazine-1-carbothioamide and al-kyl 2-(1-(1H-Indol-3-yl)ethylidene)hydrazine-1-carbodithioate in ethanolic triethylamine. Structures of the newly synthesis were elucidated on the basis of elemental analysis, spectral data, and alternative synthetic route whenever possible.

J. Heterocyclic Chem., 00, 00 (2016).

INTRODUCTION

Indole derivatives are present in both animals and plants. The most important compound of this group is tryptophan, an essential amino acid in the human diet that is a 3-substituted indole. Important alkaloids, like serotonin and tryptamin, are also indols substituted in position 3. Indole derivatives can be found in some vegetables (like cabbage), and its anticarcinogenic and antioxidant effects are subjects of research [1]. Also, it has been reported to possess a wide variety of biological properties such as antiviral agents that inhibit herpes simplex virus replication [2–4] and are fungicidal [5], anti-inflammatory [6], anticonvulsant [7], and antibacterial [8]. Other compounds derived from 3-acetylindole are used in the treatment of gastrointestinal disorder [9], are useful as antiproliferative [10,11]

and potential antiviral agents [12], are used in the treatment of cardiovascular and central nervous system disorders [13], and are also used as herpes simplex type 1 integrase inhibitors [14]. Encouraged by these observations and in continuation of our previous work in the synthesis of biologically active heterocycles [15–18], we synthesized newer heterocyclic indole derivatives with the hope to obtain better antiviral agents.

RESULTS AND DISCUSSION

Treatment of 1-(1H-indol-3-yl) ethan-1-one (1) with each of thiosemicarbazide (2a) and alkyl hydrazinecarbodithioate 2b–d in refluxing ethanol afforded 2-(1-(1H-indol-3-yl)ethylidene)hydrazine-1-carbothioamide (3a) and methyl 2-(1-(1*H*-indol-3-yl)ethylidene)-hydrazine-1carbodithioate **3b–d**, respectively (Scheme 1). Structures of **3a–d** were elucidated by elemental analysis, spectral data, and chemical transformation. Thus, **3a** was reacted with the appropriate hydrazonoyl halide **4a–h**, which afforded one isolable product formulated as 2-(2-(1-(1*H*-indol-3-yl)ethylidene)-hydrazinyl)-4-substituted 5-(aryldiazenyl)thiazole **6a–h**, respectively. Structures **6a–h** were elucidated by elemental analysis, spectral data, and alternative synthetic route. Thus, treatment of benzenediazonium chloride with 2-(2-(1-(1*H*-indol-3-yl)ethylidene)hydrazinyl)-4-

phenylthiazole (8), which was prepared via reaction of 3a with ω -bromoacetophenone, in ethanolic sodium acetate gave a product identical in all aspect (mp, mixed mp, and spectra) with compound **6f**.


To account for the formation 6, it is suggested as shown in Scheme 1 that the reaction starts with 1,3-addition of the thiol tautomer of 3a to the nitrilimine 5, generated *in situ* via dehydrohalogenation of hydrazonoyl halide 4, to give the thiohydrazonate 7, which undergoes *in situ* dehydration to give the thiazole 6 as end product.

Also, treatment of methyl 2-(1-(1H-indol-3-yl)ethylidene)hydrazinecarbodithioate (**3b**) with ethyl 2-chloro2-(2-phenylhydrazono)acetate (4d) gave one isolable product, according to thin-layer chromatography (TLC), formulated as ethyl 5-((1-(1H-indol-3-yl)ethylidene) hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (11d) (Scheme 2).

Structure **11d** was confirmed by elemental analysis, spectral data, and alternative synthesis route. Thus, 2,3 dihydro-1,3,4-thiadiazole [19] **12** was reacted with 3-acetylindole (**1**) in 2-propanol to afford a product identical in all aspects (mp, mixed mp, and spectra) with **11d**. On the other hand, again, each compound **4d** reacted with each of ethyl 2-(1-(1*H*-indol-3-yl)ethylidene)hydrazinecarbo-dithioate (**3c**) or benzyl 2-(1-(1*H*-indol-3-yl)ethylidene) hydrazinecarbodithioate (**3d**) in ethanolic triethylamine gave a product identical in all aspects (mp, mixed mp, and spectra) with **11d**.


In light of these results, the mechanism outlined in Scheme 2 seems to be the most plausible pathway for the formation of **11** from the reaction of the **3b–d** with **4** [or nitrilimide (5)]. The reaction involves the initial formation of thiohydrazonate **9**, which undergoes intramolecular cyclization as soon as it is formed to yield the intermediate **10** or via 1,3-dipolar cycloaddition of **5** to CS double bond

Scheme 1. Synthesis of thiazole derivatives 6a-h.



4, 6	R	Ar	4, 6	R	Ar
a b c d	$\begin{array}{c} CH_3\\ CH_3\\ CH_3\\ CH_3\\ CH_3\end{array}$	C ₆ H ₅ 4-CH ₃ C ₆ H ₄ 4-CH ₃ OC ₆ H ₄ 4-BrC ₆ H ₄	e f g h	CH ₃ C ₆ H ₅ 2-C ₄ H ₃ S 2-C ₁₀ H ₇	

Synthesis of Certain New Thiazole and 1,3,4-Thiadiazole Derivatives via the Utility of 3-Acetylindole




Scheme 2. Synthesis of thiadiazoles 11a-i.

of **3a–d**, which afforded intermediate **10**, which gave a final product **11** via elimination of alkyl mercaptan.

Analogously, treatment of the appropriate **3b–d** with the appropriate **4a**, **b**, **c**, and **e–h** afforded 2,3-dihydro-1,3,4-thiadiazoles **11a**, **b**, **c**, **and e–h**, respectively, in a good yield (Scheme 2).

In contrast, 1-(chloro(phenyl)methylene)-2-phenylhydrazine (13) was reacted with 3a in ethanolic triethylamine under reflux gave one isolable product, according to TLC, 2-(1-(1*H*-indol-3-yl)ethylidene)-1-(3,5-diphenyl-1,3,4-thiadiazol-2(3*H*)-ylidene)-hydrazine (17) (Scheme 3). Structure 17 was elucidated by elemental analysis, spectral data, and alternative synthetic routes. Thus, compound 13 was reacted with each of 3b–d, which afforded a product identical in all aspects (mp, mixed mp, and spectra) with 17. Also, compound 17 was obtained via reaction of 2hydrazono-3,5-diphenyl-2,3-dihydro-1,3,4-thiadiazole [20] (18) with 3-acetylindole (1) in boiling propan-2-ol.

Scheme 3. Synthesis of 2-((1-(1H-indol-3-yl)ethylidene)hydrazono)-3,5-diphenyl-2,3-dihydro-1,3,4-thiadiazole (17).




Journal of Heterocyclic Chemistry DOI 10.1002/jhet

The mechanism outlined in Scheme 3 seems to be the most plausible pathway for the formation of **17** from the reaction of the **3a** with **13**. The reaction involves the initial formation of thiohydrazonate **14**, which undergoes cyclization as soon as it is formed to yield the final product **17** via loss of one molecule of ammonia. Also, the mechanism of synthesis **17** via reaction **13** with the appropriate **3b–d** may be taken through two ways: (1) the reaction involves the initial formation of thiohydrazonate **15**, which undergoes intramolecular cyclization as soon as it is formed to yield the intermediate **16**, and (2) via 1,3-dipolar cycloaddition of **13A** to CS double bond of **3a–d** afforded intermediate **16**, which undergoes *in situ* to a final product **17** via elimination of alkyl mercaptan.

Treatment of **3a** with maleic anhydride in ethanol under reflux gave one isolable product according to TLC. The product was formulated as follows: N'-(1-(1H-indol-3-yl) ethylidene)-2,5-dioxo-2,5-dihydro-1H-pyrrole-1-carbothiohydrazide (**19**) or 2-(2-((1-(1H-indol-3-yl)ethylidene) hydrazono)-4-oxothiazolidin-5-yl)acetic acid (**20**) (Scheme 3). Compound **19** was ruled out on the basis of spectral data [¹H NMR spectrum showed δ = 2.35 (s, 3H, CH₃), 2.85–2.91 (dd, 2H, CH₂), 4.32–4.36 (q, 1H, CH thiazolidone H-5), 7.1–8.3 (m, 5H, ArH's), 8.45 (s, br, 2H, NH and OH), 11.51 (s, br, 1H, NH)].

Analogously, **3** reacted with phthalic anhydride in boiling ethanol afforded N'-(1-(benzofuran-3-yl)ethylidene)-1,3-dioxoisoindoline-2-carbothiohydrazide (**21**) in a good yield. Structure of **21** was elucidated on basis of elemental analysis and spectral data. ¹H NMR spectrum showed signals at δ = 2.46 (s, 3H, CH₃), 7.16–8.29 (m, 9H, ArH's, and indole H-2), 11.89 (s, br, 1H, NH).

Scheme 4. Synthesis of thiazolide derivates 20 and 22 and 1,3-dioxoisoindoline-2-carbothiohydrazide (21).



Finally, 3 was reacted with dimethvl acetylenedicarboxylate in ethanol under reflux gave one product, according TLC, isolable formulated as follows: methyl 2-(-2-((-1-(benzofuran-3-yl)ethylidene) hydrazono)-4-oxothiazolidin-5-ylidene)acetate (22)or methyl 2-((-1-(1H-indol-3-yl)ethylidene)hydrazono)-4oxo-3,4-dihydro-2H-1,3-thiazine-6-carboxylate (23) or dimethyl 2-((1-(1H-indol-3-yl)ethylidene)hydrazono) thiazolidine-4,5-dicarboxylate (24) (Scheme 4). Structures 23 and 24 were excluded on the basis of ¹H NMR spectrum, which showed signals at $\delta = 2.43$ (s, 3H, CH₃), 3.79 (s, 3H, COOCH₃), 6.69 (s, 1H, C=CH), 6.91-8.29 (m, 5H, Ar-H), 11.88 (s, 1H, D₂O-exchangeable NH), 12.62 (s, 1H, D₂O-exchangeable NH).

CONCLUSION

In conclusion, reaction of 2-(1-(1*H*-indol-3-yl)ethylidene)hydrazine-1-carbothioamide and alkyl 2-(1-(1*H*-indol-3-yl)ethylidene)hydrazine-1-carbodithioate with hydrazonoyl halides yielded the condensation products 5-arylazothiazoles **6** and 1,3,4-thiadiazoles **11** and **17**, respectively. Also, 2-(1-(1*H*-indol-3-yl)ethylidene)hydrazine-1-carbothioamide was reacted each with maleic anhydride, phthalic anhydride, and dimethyl acetylenes, which afforded **20–22**, respectively. The structures of the newly synthesized compounds were confirmed by spectral data, elemental analyses, and alternate syntheses whenever possible.

EXPERIMENTAL

Melting points were measured on an Electrothermal IA 9000 (Bibby Sci. Lim. Stone, Staffordshire, UK) series digital melting point apparatus. IR spectra were recorded in potassium bromide discs on PyeUnicam SP 3300 and Shimadzu FTIR 8101 PC infrared spectrophotometers. NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer operating at 300 MHz (¹H NMR) and run in deuterated dimethylsulfoxide (DMSO-*d*₆). Chemical shifts were related to those of the solvent. Mass spectra were recorded on a Shimadzu GCMS-QP1000 EX mass spectrometer at 70 eV. Elemental analyses were measured by using a German made Elementarvario LIII CHNS analyzer. Compound **3a** [21] and hydrazonoyl halides [22–27] **4**, **13**, and **2b–d** [28] were prepared as reported in the literature.

Synthesis of alkyl 2-(1-(5-methyl-1-phenyl-1H-1,2,3-triazol-4-yl)ethylidene) hydrazine carbodithioate (3b-d). To a solution of 3-acetyl-1*H*-indole 1 (1.59 g, 10 mmol) in 2propanol (20 mL), alkyl hydrazinecarbodithioate **2b-d** (10 mmol) was added. The mixture was stirred at room Month 2016

temperature for 2 h. The solid product was filtered off and recrystallized from ethanol to afford **3b–d**.

Methyl 2-(1-(1H-indol-3-yl)ethylidene)hydrazinecarbodithioate (3b). Yellow solid; 69%; mp 203–205°C; IR (KBr): v=3444, 3157 (2NH), 2943 (CH), 1604 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆): $\delta=2.43$ (3H, s, CH₃), 2.51 (3H, s, CH₃), 7.13–8.28 (6H, m, Ar–H and NH), 11.88 (1H, s, NH); mass spectrometry (MS) *m*/*z* (%): 263 (M⁺, 30), 220 (50), 176 (63), 100 (72), 86 (100), 56 (93). *Anal.* Calcd for C₁₂H₁₃N₃S₂ (263.38): C, 54.72; H, 4.97; N, 15.95. Found: C, 54.64; H, 4.86; N, 15.79%.

Ethyl 2-(1-(1H-indol-3-yl)ethylidene)hydrazinecarbodithioate (3c). Yellow solid; 64%; mp 181–183°C; IR (KBr): v=3417, 3126 (2NH), 2912 (CH), 1591 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6): $\delta = 1.41$ (3H, t, <u>CH₃CH₂S), 2.51 (3H, s, CH₃), 3.40 (2H, q, SCH₂CH₃),</u> 7.11–8.22 (6H, m, Ar–H and NH), 11.82 (1H, s, NH); MS m/z (%): 277 (M⁺, 73), 262 (50), 248 (100), 206 (51), 192 (74), 176 (50), 107 (21). *Anal.* Calcd for C₁₃H₁₅N₃S₂ (277.41): C, 56.28; H, 5.45; N, 15.15. Found: C, 56.21; H, 5.36; N, 15.04%.

Benzyl 2-(1-(1H-indol-3-yl)ethylidene)hydrazinecarbodithioate (3d). Yellow solid; 65%; mp 170–172°C; IR (KBr): v=3419, 3234 (2NH), 2968 (CH), 1604 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6): $\delta=2.42$ (3H, s, CH₃), 4.58 (2H, s, CH₂), 7.02–8.48 (10H, m, Ar–H), 11.62 (1H, s, NH), 12.22 (1H, s, NH); MS *m*/*z* (%): 339 (M⁺, 100), 265 (30), 164 (62), 106 (40), 79 (39). *Anal.* Calcd for C₁₈H₁₇N₃S₂ (339.48): C, 63.68; H, 5.05; N, 12.38. Found: C, 63.47; H, 5.01; N, 12.24%.

Synthesis of 4-methyl-2-(2-(1-(5-methyl-1-phenyl-1H-1,2,3triazol-4-yl)ethylidene) hydrazinyl)-5-(aryldiazenyl)thiazole (6a–h). A mixture of thiosemicarbazone 3a (0.232 g, 1 mmol) and the appropriate hydrazonoyl halides 4 (1 mmol) in dioxane (20 mL) containing triethylamine (0.07 mL) was refluxed for 6 h and allowed to cool, and the solid that formed was filtered off, washed with EtOH, dried, and recrystallized from dimethylformamide (DMF) to give the corresponding 1,3,4-thiadiazolines 6a–h. The products 6a–h together with their physical constants are listed subsequently.

2-(2-(1-(1H-Indol-3-yl)ethylidene)hydrazinyl)-4-methyl-5-(phenyldiazenyl)thiazole (6a). Red solid (70% yield); mp 242–244°C (lit mp (21)). ¹³C NMR (75 MHz, DMSO- d_6) δ =14.7, 16.7, 112.4, 116.6, 120.2, 121.7, 122.5, 122.6, 125.1, 126.0, 129.3, 129.9, 130.4, 135.7, 135.6, 152.8, 154.0, 166.0.

2-(2-(1-(1H-Indol-3-yl)ethylidene)hydrazinyl)-4-methyl-5-(ptolyldiazenyl)thiazole (6b). Red solid (73% yield); mp 258–260°C; IR (KBr) v=3437, 3234 (2NH), 1577 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) $\delta=2.26$ (s, 3H, CH₃), 2.57 (s, 3H, CH₃), 3.56 (s, 3H, CH₃), 7.12– 8.53 (m, 9H, Ar–H), 10.42 (s, 1H, D₂O-exchangeable NH), 11.77 (s, 1H, D₂O-exchangeable NH); ¹³C NMR (75 MHz, DMSO- d_6) δ = 14.7, 16.7, 112.4, 116.6, 120.5, 121.2, 122.6, 122.5, 125.0, 126.1, 129.1, 129.8, 130.4, 135.6, 135.9, 152.4, 154.0, 166.0; MS, m/z (%): 388 (M⁺, 23), 373 (29), 277 (41), 105 (100), 77 (50). *Anal.* Calcd for C₂₁H₂₀N₆S (388.49): C, 64.92; H, 5.19; N, 21.63. Found: C, 64.74; H, 5.16; N, 21.48%.

2-(2-(1-(1H-Indol-3-y))ethylidene)hydrazinyl)-5-((4-methoxyphenyl)diazenyl)-4-methylthiazole (6c). Red solid (67% yield); mp 212–214°C; IR (KBr) v=3431, 3248 (2NH), 1578 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ =2.56 (s, 3H, CH₃), 3.56 (s, 3H, CH₃), 3.74 (s, 3H, OCH₃), 6.92–8.55 (m, 9H, Ar–H), 10.37 (s, 1H, D₂O-exchangeable NH), 11.73 (s, 1H, D₂O-exchangeable NH); ¹³C NMR (75 MHz, DMSO-d₆) δ =14.37, 16.37, 55.34 (OCH₃), 112.45, 114.40, 116.67, 120.50, 121.52, 122.44, 124.62, 125.25, 126.09, 129.73, 135.45, 135.87, 148.03, 154.01, 154.01, 161.32, 166.06; MS, *m*/*z* (%): 404 (M⁺, 32), 359 (44), 225 (59), 105 (100), 77 (71). Anal. Calcd for C₂₁H₂₀N₆OS (404.49): C, 62.36; H, 4.98; N, 20.78. Found: C, 62.32; H, 4.90; N, 20.59%.

2-(2-(1-(1H-Indol-3-yl)ethylidene)hydrazinyl)-5-((4-bromophenyl)diazenyl)-4-methylthiazole (6d). Orange solid (67% yield); mp 264–265°C (lit mp (21)).

2-(2-(1-(1H-Indol-3-yl)ethylidene)hydrazinyl)-5-((4-chlorophenyl)diazenyl)-4-methylthiazole (6e). Orange solid (72% yield); mp 256–258°C (lit mp (21)).

2-(2-(1-(1H-Indol-3-yl)ethylidene)hydrazinyl)-4-phenyl-5-(phenyldiazenyl)thiazole (6f). Orange solid (68% yield); mp 243–245°C; IR (KBr) v=3412, 3278 (2NH), 1602 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ =2.59 (s, 3H, CH₃), 3.56 (s, 3H, CH₃), 7.00–8.29 (m, 15H, Ar–H), 10.60 (s, 1H, D₂O-exchangeable NH), 11.79 (s, 1H, D₂O-exchangeable NH); ¹³C NMR (75 MHz, DMSO-d₆) δ =17.3, 107.4, 110.8, 117.2, 119.7, 121.0, 121.3, 126.7, 129.0, 130.3, 131.1, 133.3, 135.8, 136.6, 155.0, 155.3, 171.6; MS, *m*/*z* (%): 436 (M⁺, 53), 380 (75), 202 (100), 178 (57). Anal. Calcd for C₂₅H₂₀N₆S (436.53): C, 68.78; H, 4.62; N, 19.25. Found: C, 68.65; H, 4.64; N, 19.13%.

2-(2-(1-(1H-Indol-3-yl)ethylidene)hydrazinyl)-5-(phenyldiazenyl) 4-(thiophen-2-yl)thiazole (6g). Orange solid (67% yield); mp 243–245°C; IR (KBr) v=3409, 3257 (2NH), 1635 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) δ =2.63 (s, 3H, CH₃), 3.56 (s, 3H, CH₃), 7.01–8.57 (m, 13H, Ar– H), 10.62 (s, 1H, D₂O-exchangeable NH), 11.81 (s, 1H, D₂O-exchangeable NH); MS, m/z (%): 442 (M⁺, 100), 354 (61), 264 (45), 228 (79), 131(48). *Anal.* Calcd for C₂₃H₁₈N₆S₂ (442.56): C, 62.42; H, 4.10; N, 18.99. Found: C, 62.36; H, 4.06; N, 18.69%.

2-(2-(1-(1H-Indol-3-yl)ethylidene)hydrazinyl)-4-(naphthalen-2yl-5-(phenyl diazenyl)thiazole (6h). Orange solid (60% yield); mp 267–269°C; IR (KBr) v=3415, 3298 (2NH), 1614 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ = 2.61 (s, 3H, CH₃), 3.56 (s, 3H, CH₃), 7.25–8.36 (m, 13H, Ar–H), 10.67 (s, 1H, D₂O-exchangeable NH), 11.85 (s, 1H, D₂O-exchangeable NH); MS, *m/z* (%): 486 (M⁺, 100), 422 (86), 376 (78), 335 (54), 188 (29), 147 (18). *Anal.* Calcd for C₂₉H₂₂N₆S (486.59): C, 71.58; H, 4.56; N, 17.27. Found: C, 71.48; H, 4.43; N, 17.20%.

Synthesis of 2-(2-(1-(1H-indol-3-yl)ethylidene)hydrazinyl)-4-To a solution of 2-(1-(1H-indol-3-yl) phenylthiazole (8). (2.3 g, ethylidene)hydrazine-1-carbothioamide (3a)10 mmol) in ethanol (20 mL), phenacyl bromide (0.197 g, 1 mmol) was added. The mixture was refluxed for 2h and then cooled to room temperature. The solid product was filtered off, washed with ethanol, and recrystallized from ethanol to afford the thiazole derivative 9 as white solid (75% yield); mp 178–180°C; IR (KBr) v = 3425, 3161 (2NH), 1612 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) $\delta = 2.66$ (s, 3H, CH₃), 3.93 (s, 3H, CH₃), 6.96– 8.42 (m, 11H, Ar-H and thiazole H-5), 10.81 (s, 1H, D₂O-exchangeable NH), 12.09 (s, 1H, D₂O-exchangeable NH); MS, m/z (%): 332 (M⁺, 17), 179 (59), 138 (100), 108 (63), 65 (69). Anal. Calcd for C₁₉H₁₆N₄S (332.42): C, 68.65; H, 4.85; N, 16.85. Found: C, 68.69; H, 4.72; N, 16.76%.

Alternate synthesis of 6f. To a solution of 8 (0.332 g, 1 mmol) in ethanol (20 mL) was added sodium acetate trihydrate (0.138 g, 1 mmol), and the mixture was cooled to 0-5°C in an ice bath. To the resulting cold solution added portionwise cold solution was а of benzenediazonium chloride [prepared by diazotizing aniline (1 mmol) dissolved in hydrochloric acid (6M, 1 mL) with a solution of sodium nitrite (0.07 g, 1 mmol) in water (2 mL)]. After complete addition of the diazonium salt, the reaction mixture was stirred for a further 30 min in an ice bath. The solid that separated was filtered off, washed with water, and finally recrystallized from DMF to give the corresponding product, 6f, which was identical in all aspects (mp, mixed mp, and IR spectra) with those obtained from reaction of 3a with 4f but in 71% yield.

General procedure for synthesis of 2-((1-(1H-indol-3-yl) ethylidene)hydrazono)-3-phenyl-5-substituted-2,3-dihydro-

1,3,4-thiadiazole derivatives (11a–i). To a mixture of alkyl carbodithioate **3b–d** (0.305 g, 1 mmol) and the appropriate hydrazonoyl halides **4** (1 mmol) in ethanol (20 mL), triethylamine (0.5 mL) was added, the mixture was stirred at room temperature for 2 h. The resulting solid was collected and recrystallized from DMF to give the corresponding 1,3,4-thiadiazolines **8a–i**. The products **8a–i** together with their physical constants are listed subsequently.

1-(5-((1-(1H-Indol-3-yl)ethylidene)hydrazono)-4-phenyl-4,5dihydro-1,3,4-thiadiazol-2-yl)ethanone (11a). Yellow solid (79% yield); mp 234–336°C; IR (KBr): v=3259 (NH), 1697 (C=O) cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆) δ = 2.37 (3H, s, CH₃), 3.89 (3H, s, CH₃), 6.84–8.29 (10H, m, Ar–H), 11.87 (s, 1H, D₂O-exchangeable NH); ¹³C NMR (75 MHz, DMSO-*d*₆) δ = 20.2, 24.9, 112.2, 113.6, 120.2, 121.4, 122.5, 123.0, 127.3, 129.8, 135.6, 138.9, 150.4, 153.7, 157.8, 191.0; MS, *m/z* (%): 375 (M⁺, 52), 285 (87), 231 (633), 163 (70), 43 (100). *Anal.* Calcd for C₂₀H₁₇N₅OS (375.45): C, 63.98; H, 4.56; N, 18.65. Found: C, 63.81; H, 4.48; N, 18.59%.

1-(5-((1-(1H-Indol-3-yl)ethylidene)hydrazono)-4-(ptolyl)-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethanone (11b). Yellow solid (72% yield); mp 234–336°C; IR (KBr): v=3311 (NH), 1699 (C=O) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ =2.22 (3H, s, CH₃), 2.35 (3H, s, CH₃), 3.87 (3H, s, CH₃), 7.05–8.29 (9H, m, Ar–H), 11.89 (s, 1H, D₂O-exchangeable NH); ¹³C NMR (75 MHz, DMSO-d₆) δ =20.24, 21.6, 24.6, 112.45, 113.5, 120.2, 121.6, 122.5, 124.1, 125.7, 125.9, 129.6, 133.9, 135.6, 138.8, 150.4, 153.6, 157.8, 191.0; MS, m/z (%): 389 (M⁺, 18), 281 (27), 179 (323), 119 (53), 93 (100). Anal. Calcd for C₂₁H₁₉N₅OS (389.47): C, 64.76; H, 4.92; N, 17.98. Found: C, 64.71; H, 4.80; N, 17.75%.

I-(*5*-(*I*-(*I*H-*Indol*-*3*-*y*)*e*thylidene)hydrazono)-4-(4-chlorophenyl)-4,5dihydro-1,3,4-thiadiazol-2-yl)ethanone (11c). Yellow solid (77% yield); mp 267–169°C; IR (KBr): v=3228 (NH), 1703 (C=O) cm⁻¹; ¹H NMR (300 MHz, DMSO-*d*₆) $\delta=2.36$ (3H, s, CH₃), 3.89 (3H, s, CH₃), 7.13–8.29 (9H, m, Ar–H), 11.88 (s, 1H, D₂O-exchangeable NH); MS, *m*/ *z* (%): 409 (M⁺, 37), 325 (31), 259 (46), 143 (69), 78 (100). *Anal.* Calcd for C₂₀H₁₆ClN₅OS (409.89): C, 58.60; H, 3.93; N, 17.09. Found: C, 58.57; H, 3.74; N, 16.87%.

Ethyl 5-((1-(1H-indol-3-yl)ethylidene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (11d). Yellow solid (74% yield); mp 173–175°C; IR (KBr): v=3163(NH), 1714 (C=O), 1604 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) $\delta=1.32$ (3H, t, J=7.0, CH₂CH₃), 2.44 (3H, s, CH₃), 4.22 (2H, q, J=7.0, CH₂CH₃), 6.82– 8.28 (10H, m, Ar–H), 11.88 (s, 1H, D₂O-exchangeable NH); ¹³C NMR (75 MHz, DMSO-d₆): $\delta=14.3$, 20.0, 62.5, 107.2, 112.1, 119.0, 121.2, 121.5, 127.2, 129.4, 131.2, 133.5, 135.6, 137.3, 149.6, 159.5, 159.4, 161.4; MS, m/z (%): 405 (M⁺, 12), 284 (27), 147 (64), 122 (43), 105 (100), 77 (34). Anal. Calcd for C₂₁H₁₉N₅O₂S (405.47): C, 62.21; H, 4.72; N, 17.27. Found: C, 62.05; H, 4.68; N, 17.13%.

Ethyl 5-((1-(1H-indol-3-yl)ethylidene)hydrazono)-4-(p-tolyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate (11e). Yellow solid (72% yield); mp 180–182°C; IR (KBr): v=3159 (NH), 1703 (C=O), 1603 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) $\delta=1.31$ (3H, t, J=7.0, CH₂CH₃), 2.20 (3H, s, CH₃), 2.44 (3H, s, CH₃), 4.18 (2H, q, J=7.0, CH₂CH₃), 7.02–8.29 (9H, m, Ar–H), 11.88 (s, 1H, D₂O-exchangeable NH); MS, m/z (%): 419 (M⁺, 13), 360 (96), 222 (60), 151 (100), 130 (28), 83 (37). *Anal.* Calcd for C₂₂H₂₁N₅O₂S (419.50): C, 62.99; H, 5.05; N, 16.69. Found: C, 62.86; H, 5.02; N, 16.53%.

Ethyl 5-((1-(1H-indol-3-yl)ethylidene)hydrazono)-4-(4chlorophenyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate

(11f). Yellow solid (77% yield); mp 212–214°C; IR (KBr): v=3157 (NH), 1726 (C=O), 1612 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) $\delta=1.28$ (3H, t, J=7.0, CH₂CH₃), 2.44 (3H, s, CH₃), 4.19 (2H, q, J=7.0, CH₂CH₃), 7.13–8.28 (9H, m, Ar–H), 11.88 (s, 1H, D₂Oexchangeable NH); ¹³C NMR (75 MHz, DMSO- d_6): $\delta=14.3$, 20.0, 21.1, 62.8, 107.2, 114.1, 118.3, 119.0, 121.5, 128.5, 129.4, 132.2, 133.5, 135.6, 137.3, 149.6, 159.5, 159.4, 161.4; MS, m/z (%): 439 (M⁺, 12), 346 (14), 198 (71), 105 (62), 118 (38), 77 (100). Anal. Calcd for C₂₁H₁₈CIN₅O₂S (439.92): C, 57.33; H, 4.12; N, 15.92. Found: C, 57.23; H, 4.11; N, 15.75%.

5-((1-(1H-Indol-3-yl)ethylidene)hydrazono)-N,4-diphenyl-4,5dihydro-1,3,4-thiadiazole-2-carboxamide (11g). Yellow solid (83% yield); mp 267–279°C; IR (KBr): v=3288, 3161 (NH), 1680 (C=O) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ =2.44 (3H, s, CH₃), 7.15–8.28 (15H, m, Ar–H), 11.17 (s, 1H, D₂O-exchangeable NH), 11.89 (s, 1H, D₂O-exchangeable NH); MS, *m*/*z* (%): 452 (M⁺, 4), 377 (48), 253 (17), 193 (16), 142 (38), 91(100), 84 (70). Anal. Calcd for C₂₅H₂₀N₆OS (452.53): C, 66.35; H, 4.45; N, 18.57. Found: C, 66.29; H, 4.35; N, 18.39%.

(5-((1-(1H-Indol-3-yl)ethylidene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)(phenyl)methanone (11h). Yellow solid (80% yield); mp 252–254°C; IR (KBr): v=3248 (NH), 1697 (C=O) cm⁻¹; ¹H NMR (300 MHz, DMSO-d₆) δ =2.42 (3H, s, CH₃), 7.19–8.29 (15H, m, Ar–H), 11.88 (s, 1H, D₂O-exchangeable NH); MS, *m/z* (%): 437 (M⁺, 100), 346 (29), 331 (12), 273 (20), 217 (38), 93 (63). Anal. Calcd for C₂₅H₁₉N₅OS (437.52): C, 68.63; H, 4.38; N, 16.01. Found: C, 68.59; H, 4.22; N, 15.96%.

(5-((1-(1H-Indol-3-yl)ethylidene)hydrazono)-4-phenyl-4,5-dihydro-1,3,4-thiadiazol-2-yl)(thiophen-2-yl)methanone

(11i). Yellow solid (78 yield); mp 243–245°C; IR (KBr): v=3157(NH), 1690 (C=O), 1595 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) $\delta=2.40$ (3H, s, CH₃), 6.87–8.28 (13H, m, Ar–H), 11.89 (s, 1H, D₂O-exchangeable NH); MS, *m*/*z* (%): 443 (M⁺, 38), 330 (17), 261 (11), 139 (48), 125 (100). *Anal.* Calcd for C₂₃H₁₇N₅OS₂ (443.54): C, 62.28; H, 3.86; N, 15.79. Found: C, 62.13; H, 3.80; N, 15.49%.

Synthesis of 2-((1-(1H-indol-3-yl)ethylidene)hydrazono)-3,5-diphenyl-2,3-dihydro-1,3,4-thiadiazole (15).

Method A. To a mixture of alkyl carbodithioate 3b-d (1 mmol) and *N'*-phenylbenzohydrazonoyl chloride 11 (0.230 g, 1 mmol) in ethanol (10 mL), triethylamine (0.5 mL) was added, and the mixture was stirred at room temperature for 2 h. The resulting solid was collected and recrystallized from DMF to give 1,3,4-thiadiazoline 11 as

yellow solid (78% yield); mp 269–271°C; IR (KBr): v=3159 (NH), 1612 (C=N) cm⁻¹; ¹H NMR (300 MHz, DMSO- d_6) $\delta=2.44$ (3H, s, CH₃), 7.13–8.28 (15H, m, Ar–H), 11.89 (s, 1H, D₂O-exchangeable NH); ¹³C NMR (75 MHz, DMSO- d_6) $\delta=20.6$, 112.4, 113.6, 119.5, 121.0, 122.5, 123.0, 125.3, 125.7, 126.1, 129.2, 130.0, 131.2, 132.8, 135.5, 138.0, 153.7, 156.3, 167.4; MS, *m/z* (%): 409 (M⁺, 28), 303 (90), 273 (47), 165 (100), 77 (42). *Anal.* Calcd for C₂₄H₁₉N₅S (409.51): C, 70.39; H, 4.68; N, 17.10. Found: C, 70.24; H, 4.48; N, 17.03%.

Method B. A mixture of thiosemicarbazone **3a** (0.232 g, 1 mmol) and *N'*-phenylbenzohydrazonoyl chloride **13** (0.230 g, 1 mmol) in dioxane (10 mL) containing triethylamine (0.07 mL) was refluxed for 6 h and allowed to cool, and the solid formed was filtered off, washed with EtOH, dried, and recrystallized from DMF to give the corresponding product, **11**, which was identical in all aspects (mp, mixed mp, and IR spectra) with those obtained from method A but in 62% yield.

Synthesis of compounds 20–22. To a solution of thiosemicarbazone 3a (0.232 g, 1 mmol) in dry methanol (20 mL) was added maleic anhydride or phthalic anhydride or dimethyl acetylene dicarboxylate (1 mmol). The solution was refluxed for 2 h. The precipitate was filtered, washed with methanol, and recrystallized from DMF to give compounds 20–22, respectively.

2-(2-((1-(1H-Indol-3-yl)ethylidene)hydrazono)-4-oxothiazolidin-5-yl) acetic acid (20). White solid (69% yield); mp 305–307°C; IR (KBr): v= 3419, 3406, 3244 (2NH and OH), 1730, 1670 (2C=O), 1606 (C=N) cm⁻¹; ¹H NMR (DMSO-d₆): δ = 2.44 (s, 3H, CH₃), 2.85 (dd, 1H, CH₂), 2.94(dd, 1H, CH₂), 4.33 (dd, 1H, CH), 6.70–8.41 (m, 6H, Ar–H and NH), 11.51 (s, 1H, D₂O-exchangeable NH), 11.94 (s, 1H, D₂O-exchangeable OH); ¹³C NMR (75 MHz, DMSO-d₆) δ = 15.0, 36.1, 41.2, 107.0, 112.1, 119.3, 121.0, 121.3, 130.2, 133.7, 137.3, 156.6, 159.5, 173.5, 177.0; MS *m*/*z* (%): 330 (M⁺, 21), 312 (81), 210 (25), 150 (100), 104 (29), 76 (17). Anal. Calcd for C₁₅H₁₄N₄O₃S (330.36): C, 54.53; H, 4.27; N, 16.96. Found: C, 54.38; H, 4.17; N, 16.82%.

N'-(1-(1H-Indol-3-yl)ethylidene)-1,3-dioxoisoindoline-2carbothiohydrazide (21). White solid (73% yield); mp 326–328°C; IR (KBr): v=3406, 3186 (2NH), 1627 (C=O) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ =2.44 (s, 3H, CH₃), 7.16–8.29 (m, 9H, Ar–H), 11.9 (s, 1H, D₂O-exchangeable NH), 11.89 (s, 1H, D₂O-exchangeable NH), 11.89 (s, 1H, D₂O-exchangeable NH); MS *m*/*z* (%): 362 (M⁺, 100), 347 (59), 291 (53), 263 (25), 83 (43). *Anal.* Calcd for C₁₉H₁₄N₄O₂S (362.41): C, 62.97; H, 3.89; N, 15.46. Found: C, 62.85; H, 3.77; N, 15.37%.

Methyl 2-(2-((1-(1H-indol-3-yl)ethylidene)hydrazono)-4oxothiazolidin-5-ylidene) acetate (22). Canary yellow solid (78% yield); mp 288–290°C; IR (KBr): v=3412, 3159 (2NH), 1694, 1686 (2C=O), 1602 (C=N) cm⁻¹; ¹H NMR (DMSO- d_6): δ =2.43 (s, 3H, CH₃), 3.79 (s, 3H, COOCH₃), 6.69 (s, 1H, C=CH), 6.91–8.29 (m, 5H, Ar–H), 11.88 (s, 1H, D₂O-exchangeable NH), 12.62 (s, 1H, D₂O-exchangeable NH); MS m/z (%): 342 (M⁺, 8), 307 (47), 190 (100), 160 (93), 77 (52). Anal. Calcd for C₁₆H₁₄N₄O₃S (342.37): C, 56.13; H, 4.12; N, 16.36. Found: C, 56.04; H, 4.03; N, 16.20%.

REFERENCES AND NOTES

[1] Hidgon, J. V.; Delage, B. W.; Dashwood, R. H. Pharmacol Res 2007, 55, 224.

- [2] Chen, J. J.; Wei, Y.; Drach, J. C.; Townsend, L. B. J. Med Chem 2000, 43, 2449.
- [3] Williams, J. D.; Chen, J. J.; Drach, J. C.; Townsend, L. B. J Med Chem 2004, 47, 5753.
- [4] Giampieri, M.; Balbi, A.; Mazzei, M.; Colla, P. L.; Ibba, C.; Loddo, R. Antiviral Res 2009, 83, 179.
- [5] Akagi, T.; Mitani, S.; Komyoji, T.; Nagatani, K. J. Pestic Sci 1995, 20, 279.
- [6] Shin, J. S.; Yun, C. H.; Cho, Y. W.; Baek, N. I.; Choi, M. S.; Jeong, T. S.; Chung, H. G.; Lee, K. T. J Med Food 2011, 14, 1527.
- [7] Adel, A. E.; Abdou, N. A.; El-Taher, Z. S.; Hosny, A. E.; Alexandria, J. Pharm Sci 1993, 7, 99.
- [8] Dandia, A.; Sehgal, V.; Singh, P. Indian J. Chem 1993, 32B, 1288.
 [9] Ferro, S.; Barreca, M. L.; De Luca, L.; Rao, A.; Monforte, A. M.;
- Debyser, Z.; Witvrouw, M.; Chimirri, A. A. Arch Pharm 2007, 340, 292. [10] Srinivas, P.; Subramanian, A. R.; Raghavan, S. A. V.;
- Jagadeesh, B. R. Pharm Pharmacol Commun 1999, 5, 95.

- [12] Almerico, A. M.; Lauria, A.; Diana, P.; Barraja, P.; Cirrincione, G.; Dattolo, G. Arkivoc 2000, (ix), 486.
- [13] Francis, K. D.; Mary, G. L.; Raymond, M. K. PCT Int Appl WO 1994 9427987; Chem Abstr, 1996, 122, 187597.
- [14] Pais, G. C. G.; Zhang, X.; Marchand, C.; Neamati, N.;
- Cowansage, K.; Svarovskaia, E. S.; Pathak, V. K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T. R. J. Med Chem 2002, 45, 3184.
- [15] Abdelhamid, A. O.; Gomha, S. M. J.Chem 2013, 2013, 1.
 [16] Gomha, S. M.; Shawali, S. A.; Abdelhamid, A. O. Turk J.
- Chem 2014, 38, 865. [17] Gomha, S. M.; Ahmed, S. A.; Abdelhamid, A. O. Molecules
- [17] Gomna, S. M.; Anmed, S. A.; Abdeinamid, A. O. Molecules 2015, 20, 1356.
- [18] Gomha, S. M.; Salah, T. A.; Abdelhamid, A. O. Monatsh Chem 2015, 146, 149.
- [19] Abdelhamid, A. O.; Zohdi, H. F.; Rateb, N. M. J Chem Res 1999, 184, 920.
- [20] Emam, H. A.; Zohdi, H. F.; Abdelhamid, A. O. J Chem Res (S) 1998 12.
- [21] Abdel-Gawad, H.; Mohamed, H. A.; Dawood, K. M.; Badria, F. A. R. Chem Pharm Bull 2010, 58, 1529.
 - [22] Wolkoff, P. Can J. Chem 1975, 53, 1333.
 - [23] Eweiss, N. F.; Osman, A. J Heterocyclic Chem 1980, 17, 1713.
 - [24] Shawali, A. S.; Abdelhamid, A. O. Bull Chem Soc Jpn 1976, 49, 321.
 - [25] Shawali, A. S.; Osman, A. Tetrahedron 1971, 27, 2517.
- [26] Abdelhamid, A. O.; El-Shiatey, F. H. Phosphorus Sulfur Silicon Relat Elem 1988, 39, 45.
- [27] Hassaneen, H. M.; Shawali, A. S.; Elwan, N. M.; Abounada, N. M. Sulfur Lett 1992, 13, 273.
- [28] Klayman, D. L.; Bartosevich, J. F.; Griffin, T. S.; Mason, C. J.; Scovill, J. P. J. Med Chem 1979, 22, 855.